Mineralys Therapeutics (Nasdaq: MLYS) announced that it granted inducement equity awards on February 9, 2026, to two new non-executive employees under its 2025 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The awards consist of stock options covering 33,504 shares and 25,128 restricted stock units (RSUs). The stock options vest over four years with 25% vesting after one year and monthly installments thereafter, while the RSUs vest in equal 25% installments on each of the first four anniversaries of the vesting commencement date.

Equity compensation—such as restricted stock units (RSUs), stock options (ISOs and NQSOs), and employee stock purchase plans—has become increasingly common, offering employees potential wealth-building opportunities but also creating complex tax considerations. Understanding vesting schedules, tax treatment, strategies like Section 83(b) elections and net unrealized appreciation, and risks such as concentrated stock positions is essential to maximizing value and avoiding costly surprises. With proper planning and coordination with tax and financial advisors, equity awards can be transformed into a strategic asset that supports both short-term financial needs and long-term goals.

The webinar explains how first-quarter bonuses and equity vesting can lead to larger than expected tax bills because standard withholding may not be sufficient. It covers key planning tools for executives, such as safe harbor election rules, making estimated tax payments, and how different types of equity compensation (like RSUs, ISOs, and NSOs) affect tax obligations. The presenter also highlights time-sensitive actions that can help reduce underpayment penalties and better align your withholding with your actual tax liability.